Gene Therapy for Leber Hereditary Optic Neuropathy. Initial Results

William J Feuer, Joyce C. Schiffman, Janet L Davis, Vittorio Porciatti, Phillip Gonzalez, Rajeshwari D. Koilkonda, Huijun Yuan, Anil Lalwani, Byron L Lam, John Guy

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Purpose: Leber hereditary optic neuropathy (LHON) is a disorder characterized by severe and rapidly progressive visual loss when caused by a mutation in the mitochondrial gene encoding NADH:ubiquinone oxidoreductase subunit 4 (ND4). We have initiated a gene therapy trial to determine the safety and tolerability of escalated doses of an adeno-associated virus vector (AAV) expressing a normal ND4 complementary DNA in patients with a G to A mutation at nucleotide 11778 of the mitochondrial genome. Design: In this prospective open-label trial (NCT02161380), the study drug (self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2) was intravitreally injected unilaterally into the eyes of 5 blind participants with G11778A LHON. Four participants with visual loss for more than 12 months were treated. The fifth participant had visual loss for less than 12 months. The first 3 participants were treated at the low dose of vector (5× 109 vg), and the fourth participant was treated at the medium dose (2.46× 1010 vg). The fifth participant with visual loss for less than 12 months received the low dose. Treated participants were followed for 90 to 180 days and underwent ocular and systemic safety assessments along with visual structure and function examinations. Participants: Five legally blind patients with G11778A LHON. Main Outcome Measures: Loss of visual acuity. Results: Visual acuity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart remained unchanged from baseline to 3 months in the first 3 participants. For 2 participants with 90-day follow-up, acuity increased from hand movements to 7 letters in 1 and by 15 letters in 1, representing an improvement equivalent to 3 lines. No one lost vision, and no serious adverse events were observed. Minor adverse events included a transient increase of intraocular pressure (IOP), exposure keratitis, subconjunctival hemorrhage, a sore throat, and a transient increase in neutralizing antibodies (NAbs) against AAV2 in 1 participant. All blood samples were negative for vector DNA. Conclusions: No serious safety problems were observed in the first 5 participants enrolled in this phase I trial of virus-based gene transfer in this mitochondrial disorder. Additional study follow-up of these and additional participants planned for the next 4 years is needed to confirm these preliminary observations.

Original languageEnglish (US)
JournalOphthalmology
DOIs
StateAccepted/In press - Aug 7 2015

Fingerprint

Leber's Hereditary Optic Atrophy
Genetic Therapy
Dependovirus
Safety
Visual Acuity
Electron Transport Complex I
Mitochondrial Diseases
Mutation
Mitochondrial Genome
Mitochondrial Genes
Pharyngitis
Keratitis
Diabetic Retinopathy
Neutralizing Antibodies
Intraocular Pressure
Nucleotides
Hand
Complementary DNA
Outcome Assessment (Health Care)
Hemorrhage

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Gene Therapy for Leber Hereditary Optic Neuropathy. Initial Results. / Feuer, William J; Schiffman, Joyce C.; Davis, Janet L; Porciatti, Vittorio; Gonzalez, Phillip; Koilkonda, Rajeshwari D.; Yuan, Huijun; Lalwani, Anil; Lam, Byron L; Guy, John.

In: Ophthalmology, 07.08.2015.

Research output: Contribution to journalArticle

Feuer, William J ; Schiffman, Joyce C. ; Davis, Janet L ; Porciatti, Vittorio ; Gonzalez, Phillip ; Koilkonda, Rajeshwari D. ; Yuan, Huijun ; Lalwani, Anil ; Lam, Byron L ; Guy, John. / Gene Therapy for Leber Hereditary Optic Neuropathy. Initial Results. In: Ophthalmology. 2015.
@article{ec92ac7d6a8446aea10a513b33073ccc,
title = "Gene Therapy for Leber Hereditary Optic Neuropathy. Initial Results",
abstract = "Purpose: Leber hereditary optic neuropathy (LHON) is a disorder characterized by severe and rapidly progressive visual loss when caused by a mutation in the mitochondrial gene encoding NADH:ubiquinone oxidoreductase subunit 4 (ND4). We have initiated a gene therapy trial to determine the safety and tolerability of escalated doses of an adeno-associated virus vector (AAV) expressing a normal ND4 complementary DNA in patients with a G to A mutation at nucleotide 11778 of the mitochondrial genome. Design: In this prospective open-label trial (NCT02161380), the study drug (self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2) was intravitreally injected unilaterally into the eyes of 5 blind participants with G11778A LHON. Four participants with visual loss for more than 12 months were treated. The fifth participant had visual loss for less than 12 months. The first 3 participants were treated at the low dose of vector (5× 109 vg), and the fourth participant was treated at the medium dose (2.46× 1010 vg). The fifth participant with visual loss for less than 12 months received the low dose. Treated participants were followed for 90 to 180 days and underwent ocular and systemic safety assessments along with visual structure and function examinations. Participants: Five legally blind patients with G11778A LHON. Main Outcome Measures: Loss of visual acuity. Results: Visual acuity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart remained unchanged from baseline to 3 months in the first 3 participants. For 2 participants with 90-day follow-up, acuity increased from hand movements to 7 letters in 1 and by 15 letters in 1, representing an improvement equivalent to 3 lines. No one lost vision, and no serious adverse events were observed. Minor adverse events included a transient increase of intraocular pressure (IOP), exposure keratitis, subconjunctival hemorrhage, a sore throat, and a transient increase in neutralizing antibodies (NAbs) against AAV2 in 1 participant. All blood samples were negative for vector DNA. Conclusions: No serious safety problems were observed in the first 5 participants enrolled in this phase I trial of virus-based gene transfer in this mitochondrial disorder. Additional study follow-up of these and additional participants planned for the next 4 years is needed to confirm these preliminary observations.",
author = "Feuer, {William J} and Schiffman, {Joyce C.} and Davis, {Janet L} and Vittorio Porciatti and Phillip Gonzalez and Koilkonda, {Rajeshwari D.} and Huijun Yuan and Anil Lalwani and Lam, {Byron L} and John Guy",
year = "2015",
month = "8",
day = "7",
doi = "10.1016/j.ophtha.2015.10.025",
language = "English (US)",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Gene Therapy for Leber Hereditary Optic Neuropathy. Initial Results

AU - Feuer, William J

AU - Schiffman, Joyce C.

AU - Davis, Janet L

AU - Porciatti, Vittorio

AU - Gonzalez, Phillip

AU - Koilkonda, Rajeshwari D.

AU - Yuan, Huijun

AU - Lalwani, Anil

AU - Lam, Byron L

AU - Guy, John

PY - 2015/8/7

Y1 - 2015/8/7

N2 - Purpose: Leber hereditary optic neuropathy (LHON) is a disorder characterized by severe and rapidly progressive visual loss when caused by a mutation in the mitochondrial gene encoding NADH:ubiquinone oxidoreductase subunit 4 (ND4). We have initiated a gene therapy trial to determine the safety and tolerability of escalated doses of an adeno-associated virus vector (AAV) expressing a normal ND4 complementary DNA in patients with a G to A mutation at nucleotide 11778 of the mitochondrial genome. Design: In this prospective open-label trial (NCT02161380), the study drug (self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2) was intravitreally injected unilaterally into the eyes of 5 blind participants with G11778A LHON. Four participants with visual loss for more than 12 months were treated. The fifth participant had visual loss for less than 12 months. The first 3 participants were treated at the low dose of vector (5× 109 vg), and the fourth participant was treated at the medium dose (2.46× 1010 vg). The fifth participant with visual loss for less than 12 months received the low dose. Treated participants were followed for 90 to 180 days and underwent ocular and systemic safety assessments along with visual structure and function examinations. Participants: Five legally blind patients with G11778A LHON. Main Outcome Measures: Loss of visual acuity. Results: Visual acuity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart remained unchanged from baseline to 3 months in the first 3 participants. For 2 participants with 90-day follow-up, acuity increased from hand movements to 7 letters in 1 and by 15 letters in 1, representing an improvement equivalent to 3 lines. No one lost vision, and no serious adverse events were observed. Minor adverse events included a transient increase of intraocular pressure (IOP), exposure keratitis, subconjunctival hemorrhage, a sore throat, and a transient increase in neutralizing antibodies (NAbs) against AAV2 in 1 participant. All blood samples were negative for vector DNA. Conclusions: No serious safety problems were observed in the first 5 participants enrolled in this phase I trial of virus-based gene transfer in this mitochondrial disorder. Additional study follow-up of these and additional participants planned for the next 4 years is needed to confirm these preliminary observations.

AB - Purpose: Leber hereditary optic neuropathy (LHON) is a disorder characterized by severe and rapidly progressive visual loss when caused by a mutation in the mitochondrial gene encoding NADH:ubiquinone oxidoreductase subunit 4 (ND4). We have initiated a gene therapy trial to determine the safety and tolerability of escalated doses of an adeno-associated virus vector (AAV) expressing a normal ND4 complementary DNA in patients with a G to A mutation at nucleotide 11778 of the mitochondrial genome. Design: In this prospective open-label trial (NCT02161380), the study drug (self-complementary AAV [scAAV]2(Y444,500,730F)-P1ND4v2) was intravitreally injected unilaterally into the eyes of 5 blind participants with G11778A LHON. Four participants with visual loss for more than 12 months were treated. The fifth participant had visual loss for less than 12 months. The first 3 participants were treated at the low dose of vector (5× 109 vg), and the fourth participant was treated at the medium dose (2.46× 1010 vg). The fifth participant with visual loss for less than 12 months received the low dose. Treated participants were followed for 90 to 180 days and underwent ocular and systemic safety assessments along with visual structure and function examinations. Participants: Five legally blind patients with G11778A LHON. Main Outcome Measures: Loss of visual acuity. Results: Visual acuity as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart remained unchanged from baseline to 3 months in the first 3 participants. For 2 participants with 90-day follow-up, acuity increased from hand movements to 7 letters in 1 and by 15 letters in 1, representing an improvement equivalent to 3 lines. No one lost vision, and no serious adverse events were observed. Minor adverse events included a transient increase of intraocular pressure (IOP), exposure keratitis, subconjunctival hemorrhage, a sore throat, and a transient increase in neutralizing antibodies (NAbs) against AAV2 in 1 participant. All blood samples were negative for vector DNA. Conclusions: No serious safety problems were observed in the first 5 participants enrolled in this phase I trial of virus-based gene transfer in this mitochondrial disorder. Additional study follow-up of these and additional participants planned for the next 4 years is needed to confirm these preliminary observations.

UR - http://www.scopus.com/inward/record.url?scp=84947558328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947558328&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2015.10.025

DO - 10.1016/j.ophtha.2015.10.025

M3 - Article

C2 - 26606867

AN - SCOPUS:84959453256

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

ER -